Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders
AssigneeMelior Pharmaceuticals I, Inc.
InventorsAndrew G. Reaume, Michael S. Saporito
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
Claims22
1-221. (canceled)
A pharmaceutical composition comprising:
- a) a compound of formula:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is an alkyl group and n is an integer from 0 to 5;
- and
- X is a halogen and m is an integer from 0 to 5;
- wherein m+n is less than or equal to 5;
- and
- b) a therapeutic agent chosen from:
- i) metformin;
- ii) insulin;
- iii) a PPAR agonist;
- iv) an insulin secretagogue;
- v) a sulfonylurea-based drug;
- and
- vi) an α-glucosidase inhibitor.
A pharmaceutical composition comprising:
- a) a compound of formula:
- or a pharmaceutically acceptable salt thereof;
- and
- b) a therapeutic agent chosen from:
- i) metformin;
- ii) insulin;
- iii) a PPAR agonist;
- iv) an insulin secretagogue;
- v) a sulfonylurea-based drug;
- and
- vi) an α-glucosidase inhibitor.
Dependencies are inferred from the claim text.